Business Information
The company's principal activity is to discover, investigate and develop a new class of drugs for the treatment of cancer and other pathological conditions. The company's research and development programs relate to the development of drugs to treat unresectable malignant mesothelioma, renal cell carcinoma, other cancers (epithelial malignancies), non-hodgkin's lymphoma, primary brain tumors, viral diseases, anti-inflammatory diseases, other pathological conditions such as organ transplantation and other diseases. The therapeutics is developed primarily from amphibian ribonuclei. The company is currently in discussions with several potential strategic alliance partners including major international biopharmaceutical companies to further the development and marketing of onconase (R), its principal product and other related products. The company is in its development stage.
|
|
Name |
Title
|
Email
|
| David Sidransky | Chmn. | N/A | | Kuslima Shogen | Dir., CEO | N/A | | Andrew Aromando | Sr. VP - Commercial Development, Operations | N/A | | Lawrence Kenyon | Dir., COO, CFO, Corp. Sec., Exec. VP | N/A | | Diane Scudiery | Dir. - Clinical, Regulatory Operations | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 107 | (7,810) | | 2005 | 152 | (6,462) | | 2004 | 42 | (5,070)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
